CytomX Therapeutics
Develops tumor-localized, conditionally activated oncology biologics through its PROBODY platform.
Something off on this page? Send us feedback.
Profile
Develops tumor-localized, conditionally activated biologics with PROBODY masking technology. The clinical-stage oncology portfolio centers on Varseta-M (CX-2051) and CX-801, with research collaborations rather than sales of approved medicines.
Develops conditionally activated biologics designed to localize in the tumor microenvironment through PROBODY masking technology. The design premise is intended to limit activity in healthy tissue. Internal clinical-stage programs include Varseta-M (CX-2051) and CX-801, alongside collaborations with Amgen, Bristol Myers Squibb, Regeneron, and Moderna.
Operates in a single U.S. reportable segment and has no current product-sales revenue. The model combines internal oncology development with external research and development collaborations rather than selling approved medicines.
A 2025 restructuring narrowed the focus to Varseta-M, CX-801, and research collaborations. Progress and resource needs are shaped by clinical trials, research activities, and the execution of collaboration arrangements.
Company facts
Key statistics
Year to date −24.4% · Average volume (30d) 2.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 19, 2026 | Wolfe Research | Target | $6 | |||
| May 11, 2026 | H.C. Wainwright | Target | $11 | |||
| Mar 18, 2026 | Jefferies | Reiterate | Buy | $8 | $16 | |
| Mar 16, 2026 | Oppenheimer | Target | $7 | $12 | ||
| Mar 16, 2026 | JP Morgan | Upgrade | Neutral | Overweight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.08 | −$0.09 | −16.8% | $12.4M | $1.4M | −88.6% | +2.67% |
| May 7, 2026Q1 FY26 | −$0.14 | −$0.10 | +28.6% | $4.7M | $10.3M | +119.1% | −0.50% |
| Mar 16, 2026Q4 FY25 | −$0.08 | −$0.22 | −175.0% | $7.3M | $661.0K | −91.0% | −19.26% |
| Nov 6, 2025Q3 FY25 | −$0.05 | −$0.09 | −82.5% | $7.3M | $6.0M | −18.6% | −13.60% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $50.9M | $18.7M | $6.0M | $663.0K | $10.3M | $1.4M | |
| Gross profit | $50.9M | $18.7M | $6.0M | $663.0K | $10.0M | $1.4M | |
| Operating income | $22.6M | −$1.3M | −$15.8M | −$27.9M | −$19.7M | −$23.8M | |
| Net income | $23.5M | −$154.0K | −$14.2M | −$26.5M | −$18.2M | −$20.7M | |
| Diluted EPS | $0.27 | −$0.00 | −$0.09 | −$0.17 | −$0.10 | −$0.09 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.6% | 100.0% | |
| Operating margin | 44.4% | -6.9% | -264.4% | -4,213.0% | -191.8% | -1,677.1% |
Fiscal years (4-quarter sums)FY21 $69.6M · FY22 $53.2M · FY23 $101.2M · FY24 $138.1M · FY25 $76.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $330.3M · Total debt $5.7M · Total assets $381.2M · Shareholders' equity $302.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 217.70M · Float 173.12M · 79.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 31.96M | 14.68% | 13F | May 15, 2026 |
| BlackRock, Inc. | 16.55M | 7.60% | 13G | Jul 27, 2026 |
| Bank of America Corp /DE/ | 15.13M | 7.00% | 13G | Aug 3, 2026 |
| Longitude Capital Partners V, LLC | 12.46M | 5.70% | 13G | May 15, 2026 |
| Point72 Asset Management, L.P. | 10.86M | 5.00% | 13G | Apr 16, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogden | officer: Chief Financial Officer | −1,624 | $3.05 |
| Mar 17, 2026 | Christopher Ogden | officer: Chief Financial Officer | −19,323 | $6.42 |
| Mar 17, 2026 | Marcia Belvin | officer: SVP, Chief Scientific Officer | −31,492 | $6.42 |
| Mar 17, 2026 | Sean A. McCarthy | director, officer: CEO | −118,969 | $6.42 |
| Mar 17, 2026 | Yu-Waye Chu | officer: Chief Medical Officer | −21,279 | $6.42 |
Peers
- BioAtla
Dual-CAB EpCAM×CD3 engager in advanced adenocarcinomas
- Adagene (ADR)
Masked CTLA-4 immunotherapy in MSS metastatic CRC
- Werewolf Therapeutics
Conditionally activated cytokines and masked T-cell engagers
- Xilio Therapeutics
Masked immuno-oncology platform with cytokine and TCE programs
- Janux Therapeutics
Double-masked tumor-activated T-cell engagers in Phase 1
- Xencor
Tumor-targeted CD3 bispecifics with CRC expansion cohorts
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CytomX Therapeutics | $3.20 | −0.47% | $698.8M | — | — | 38.2 | −92.4% |
| BioAtla | $1.76 | −0.56% | $2.9M | — | — | 0.3 | — |
| Adagene (ADR) | $3.68 | +0.55% | $138.5M | — | — | 14.9 | — |
| Werewolf Therapeutics | $0.9251 | −1.93% | $45.8M | — | — | 2.2 | — |
| Xilio Therapeutics | $9.02 | −0.82% | $59.2M | — | — | 0.9 | +131.2% |
| Janux Therapeutics | $18.10 | +0.50% | $1.10B | — | — | 34.5 | — |
| Xencor | $26.05 | +0.07% | $1.93B | — | — | 18.4 | +17.5% |
| Median | — | — | 8.5 | +74.3% |